comprehensive -WSS

comprehensive

author：knowledge 2025-09-27 23:31:35 - browse：955

ANDREW YATES/AFP via Getty Images

WASHINGTON — A federal judge in Delaware on Friday ruled against AstraZeneca in a case challenging the constitutionality of Medicare’s new drug price negotiation program.

Colm Connolly, chief judge of the U.S. District Court of Delaware, ruled against the company on all its major arguments. He wrote that AstraZeneca had not proved that Medicare’s new drug price negotiation program jeopardizes its constitutional property rights, and that the company didn’t have standing to challenge the guidance Medicare issued to implement the program.

The case is the first of a slew of cases filed by the pharmaceutical industry and its allies to be decided at the district court level. The Delaware ruling is a blow, as several of the other cases made similar arguments about how the program violates drugmakers’ constitutional property rights.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Humana, CVS hope to turn members into patients at clinics

explore

focus

knowledge

WSS

Was Amgen transparent enough on FDA's concern on cancer drug?

FDA panel signals lack of confidence in Amgen cancer drug data

Who is Magistrate Judge Moxila Upadhyaya in Trump's Jan. 6 case?

Humana, CVS hope to turn members into patients at clinics

Wild otter attack leads to woman being airlifted to hospital, 2 others treated for injuries

White House drug shortage group privately met with industry

entertainment

comprehensive

explore

Trump demands the U.S. pay no more for drugs than other countries … again

Colorectal cancer study finds potential in overlooked immune cell

Walensky prepares to leave CDC — and Congress — behind

Bristol 'take

Activists slam private health insurers over coverage restrictions

Physician executives need more than on

The high cost of giving birth even with insurance

Nearly two

Virginia high school admissions case could be legal follow

ER docs worry over extreme heat as a 'mass casualty event'

hotspot

Attacks on the drug industry will lead to fewer breakthroughs

Liquid biopsy for lung cancer is launched by Delfi

Attacks on the drug industry will lead to fewer breakthroughs

Dramatically reducing cancer deaths requires the PASTEUR Act

Chemotherapy drug shortage eases slightly but still widespread

CDC: Uninsured rate hit 'record low' right as states cut Medicaid

focus

focus

knowledge

leisure time